Abvc Biopharma, Inc.
ABVC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001173313
No open-market purchases or sales by Abvc Biopharma, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $1.72M in total; no superinvestor holds it.
Other share classesECOC
Q3 2021 vs. Q2 2021
How the institutions holding Abvc Biopharma, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 0 | 9 | +9 |
| Shares | 0 | 225.9K | +225.9K |
| Value | $0 | $521.0K | +$521.0K |
New holders (9)
Institutions that held Abvc Biopharma, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sabby Management, LLC | 71,558 | $165.0K | 0.04% |
| Geode Capital Management, LLC | 49,915 | $115.0K | 0.00% |
| Vanguard Group Inc | 40,560 | $94.0K | 0.00% |
| Squarepoint Ops LLC | 19,207 | $44.0K | 0.00% |
| Susquehanna International Group, LLP | 15,077 | $35.0K | 0.00% |
| Virtu Financial LLC | 13,892 | $32.0K | 0.00% |
| Credit Suisse AG | 11,709 | $27.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 3,492 | $8.00K | 0.00% |
| Bank of America Corp | 494 | $1.00K | 0.00% |
Sold out (0)
Institutions that held Abvc Biopharma, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
None.